23 compounds available
cpds from AztraZeneca with optimized pharmacological properties made available for preclinical research to explore
novel disease biology and advance scientific knowledge
700 compounds available
CNS receptor ligands. Ideal for screening or identifying recombinant orphan G protein-coupled
receptors, target validation, secondary screening, validating new assays, and for routine
pharmacological applications. Includes 13 classes of receptor ligands
769 compounds available
Includes any process that alters gene activity without changing the DNA sequence and can be transmitted to daughter cells.
177 compounds available
500 compounds available
Anti Cancer cpds shared with the Nordic academia
1 200 compounds available
FDA & EMA approved drugs (current or withdrawn). A diversified marketed drugs library designed
for repurposing/repositioning with known bioavailability and safety in humans.
378 compounds available
known kinase inhibitors available
40 compounds available
Epigenetic chemical probes
6500 compounds available
Drug repurposing set (Phase 1-3, preclinical and launched) built by The Broad Institute of MIT and
Harvard, Cambridge, Massachusetts, USA and gathered/assembled by Specs.
395 compounds available
Target and MoA. Designed by Broad Institute. Suits cellular imaging,
image analysis and high dimensional data analytics.
Read more: https://jump-cellpainting.broadinstitute.org/
1 884 compounds available
The Ancient Chinese Classical Formulas was released by the State Administration of
Traditional Chinese Medicine. From more than 100,000 prescriptions MCE has collected and sorted out
suitable monomer compounds, including licorice, ginseng, pinellia, which help to provide new ideas
and new strategies for modern drug development.
10 100 compounds available
All of the sets, except Specs Jump set, are put together and cleared of doublets:
Prestwick FDA approved, Selleck KKI, SGC bromodomain probes, AZ pharmacological toolbox, BioMol, Nordic oncology set,
Specs repurposing set, MCE traditional chinese medicine, MCE Nukleotider, MCE Epigenetics.